Evidence map›Paper›PMID 22235253›Full record

ArticlePloS one2012

FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy.

Dawn L Cooper, Stephen G Martin, James I Robinson, Sarah L Mackie, Christopher J Charles, Jackie Nam, YEAR Consortium, John D Isaacs, Paul Emery, Ann W Morgan

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 54 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. STAT3 Gain-of-Function Mutations Underlie Deficiency in Human Nonclassical CD16Journal of immunology (Baltimore, Md. : 1950) · 2021
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Activated Platelets Convert CD14Frontiers in immunology · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. By CyTOF: Heterogeneity of Human Monocytes.Arteriosclerosis, thrombosis, and vascular biology · 2017
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Dawn L CooperNIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom.
Stephen G Martin
James I Robinson
Sarah L Mackie
Christopher J Charles
Jackie Nam
YEAR Consortium
John D Isaacs
Paul Emery
Ann W Morgan
University of Leeds · GBNewcastle University · GB

Funding

Arthritis Research UK 19764Department of HealthMedical Research Council G1001518Versus Arthritis 18475
6 · The paper itself

Abstract

objectiveThe expression of FcγRIIIa/CD16 may render monocytes targets for activation by IgG-containing immune complexes (IC). We investigated whether FcγRIIIa/CD16 was upregulated in rheumatoid arthritis (RA), associated with TNF production in response to IC-stimulation, and if this predicted response to methotrexate therapy.

methodsFcγRIIIa/CD16 expression on CD14(low) and CD14++ monocytes was measured by flow cytometry in healthy controls and RA patients (early and long-standing disease). Intracellular TNF-staining was carried out after in vitro LPS or heat-aggregated immunoglobulin (HAG) activation. FcγRIIIa/CD16 expression pre- and post-steroid/methotrexate treatment was examined.

resultsIncreased FcγRIIIa/CD16 expression on CD14++ monocytes in long-standing RA patients compared to controls was demonstrated (p = 0.002) with intermediate levels in early-RA patients. HAG-induced TNF-production in RA patients was correlated with the percentage of CD14++ monocytes expressing FcγRIIIa/CD16 (p<0.001). The percentage of CD14++ monocytes expressing FcγRIIIa/CD16 at baseline in early DMARD-naïve RA patients was negatively correlated with DAS28-ESR improvement 14-weeks post-methotrexate therapy (p = 0.003) and was significantly increased in EULAR non-responders compared to moderate (p = 0.01) or good responders (p = 0.003). FcγRIIIa/CD16 expression was not correlated with age, presence of systemic inflammation or autoantibody titers.

conclusionIncreased FcγRIIIa/CD16 expression on CD14++ monocytes in RA may result in a cell that has increased responsiveness to IC-stimulation. This monocyte subset may contribute to non-response to methotrexate therapy.

Indexed as

AdultAgedAged, 80 and overArthritis, RheumatoidCase-Control StudiesFemaleGene Expression RegulationHumansLipopolysaccharide ReceptorsMaleMethotrexateMiddle AgedMonocytesReceptors, IgGRetrospective StudiesSteroidsFCGR3A protein, humanLipopolysaccharide ReceptorsMethotrexateReceptors, IgGSteroidsTumor Necrosis Factor-alpha

Identifiers

PMID22235253
PMCPMC3250404
OpenAlexW2020388502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.